Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with absolute neutrophil count of zero

References

• Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207. doi: 10.1111/bjh.13853
   PubMed Web of Science ®Google Scholar
• Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;1:76–81. doi: 10.1182/asheducation-2013.1.76
   Web of Science ®Google Scholar
• Peffault de Latour R, Tabrizi R, Marcais A, et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French reference center for aplastic anemia. Am J Hematol. 2018;93(5):635–642. doi: 10.1002/ajh.25050
   PubMed Web of Science ®Google Scholar
• Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: a single institution experience. Am J Hematol. 2017;92(12):1295–1302. doi: 10.1002/ajh.24897
   PubMed Web of Science ®Google Scholar
• Liu C, Shao Z. Aplastic anemia in China. J Transl Int Med. 2018;6(3):134–137. doi: 10.2478/jtim-2018-0028
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70:177–182. doi: 10.1111/j.1365-2141.1988.tb02460.x
   PubMed Web of Science ®Google Scholar
• Marsh JC, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70:1046–1052.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol. 1993;83:145–151. doi: 10.1111/j.1365-2141.1993.tb04645.x
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Wu CO, Nunez O, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–216. doi: 10.1111/j.1365-2141.2008.07450.x
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yagasaki H, Hama A, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011;96:771–774. doi: 10.3324/haematol.2010.032805
   PubMed Web of Science ®Google Scholar
• Yagasaki H, Shichino H, Ohara A, et al. Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children. Ann Hematol. 2014;93:747–752. doi: 10.1007/s00277-013-1984-x
   PubMed Web of Science ®Google Scholar
• Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–514.
   PubMed Web of Science ®Google Scholar
• Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2007;111:1054–1059. doi: 10.1182/blood-2007-08-099168
   PubMed Web of Science ®Google Scholar
• Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–2104. doi: 10.1182/blood-2005-03-0874
   PubMed Web of Science ®Google Scholar
• Valdez JM, Scheinberg P, Nunez O, et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726–735. doi: 10.1093/cid/ciq245
   PubMed Web of Science ®Google Scholar
• Tichelli A, Marsh JCW. Treatment of aplastic anaemia in elderly patients aged >60 years. Bone Marrow Transplant. 2013;48(2):180–182. doi: 10.1038/bmt.2012.224
   PubMed Web of Science ®Google Scholar
• Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working party of the European group for blood and marrow transplantation. Blood. 2011;117:4434–4441. doi: 10.1182/blood-2010-08-304071
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Rivera C, Kook H, et al. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein deficient clones. Br J Haematol. 2001;115:1015–1022. doi: 10.1046/j.1365-2141.2001.03191.x
   PubMed Web of Science ®Google Scholar
• Sugimori C, Chuhjo T, Feng X, et al. Minor populations of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anaemia. Blood. 2006;107:1308–1314. doi: 10.1182/blood-2005-06-2485
   PubMed Web of Science ®Google Scholar
• Afable MGII, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96:1269–1275. doi: 10.3324/haematol.2011.042622
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Saito C, Sugimori N, et al. Thymoglobuline is as effective as lymphoglobuline in Japanese patients with aplastic anemia possessing increased glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cells. Blood (ASH Annual Meeting Abstracts). 2011;118:1339.
   Web of Science ®Google Scholar
• Timeus F, Crescenzio N, Lorenzati A, et al. Paroxysmal nocturnal haemoglobinuria clones in children with acquired aplastic anaemia: a prospective single centre study. Br J Haematol. 2010;150:480–497.
   PubMed Web of Science ®Google Scholar